Literature DB >> 29413464

Harnessing genomics to improve outcomes for women with cancer in India: key priorities for research.

Sudha Sundar1, Poonam Khetrapal-Singh2, Jon Frampton3, Edward Trimble4, Preetha Rajaraman4, Ravi Mehrotra5, Roopa Hariprasad5, Arindam Maitra6, Paramjit Gill7, Vanita Suri8, Radhika Srinivasan9, Gurpreet Singh10, J S Thakur11, Preet Dhillon12, Jean-Baptiste Cazier13.   

Abstract

Cumulatively, breast, cervical, ovarian, and uterine cancer account for more than 70% of cancers in women in India. Distinct differences in the clinical presentation of women with cancer suggest underlying differences in cancer biology and genetics. The peak age of onset of breast and ovarian cancer appears to be a decade earlier in India (age 45-50 years) than in high-income countries (age >60 years). Understanding these differences through research to develop diagnosis, screening, prevention, and treatment frameworks that ar e specific to the Indian population are critical and essential to improving women's health in India. Since the sequencing of the human genome in 2001, applications of advanced technologies, such as massively parallel sequencing, have transformed the understanding of the genetic and environmental drivers of cancer. How can advanced technologies be harnessed to provide health-care solutions at a scale and to a budget suitable for a country of 1·2 billion people? What research programmes are necessary to answer questions specific to India, and to build capacity for innovative solutions using these technologies? In order to answer these questions, we convened a workshop with key stakeholders to address these issues. In this Series paper, we highlight challenges in tackling the growing cancer burden in India, discuss ongoing genomics research and developments in infrastructure, and suggest key priorities for future research in cancer in India.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29413464     DOI: 10.1016/S1470-2045(17)30726-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  6 in total

1.  QR678 & QR678 Neo Hair Growth Formulations: A Cellular Toxicity & Animal Efficacy Study.

Authors:  Rinky Kapoor; Debraj Shome; Sapna Vadera; Vaibhav Kumar; Male Shiva Ram
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-08-25

Review 2.  Heterogeneity of germline variants in high risk breast and ovarian cancer susceptibility genes in India.

Authors:  Archana Sharma-Oates; Abeer M Shaaban; Ian Tomlinson; Luke Wynne; Jean-Baptiste Cazier; Sudha Sundar
Journal:  Precis Clin Med       Date:  2018-09-22

3.  A stitch in time saves nine: Answer to the cancer burden in India.

Authors:  Ravi Mehrotra; Ravi Kaushik
Journal:  Indian J Med Res       Date:  2018-02       Impact factor: 2.375

4.  Polymorphisms of the Ras-Association Domain Family 1 Isoform A (RASSF1A) Gene are Associated with Ovarian Cancer, and with the Prognostic Factors of Grade and Stage, in Women in Southern China.

Authors:  Wei He; Pengyuan Zhang; Min Ye; Zhikang Chen; Yizi Wang; Jie Chen; Fengjuan Yao
Journal:  Med Sci Monit       Date:  2018-04-19

Review 5.  Breast cancer in India: Present scenario and the challenges ahead.

Authors:  Ravi Mehrotra; Kavita Yadav
Journal:  World J Clin Oncol       Date:  2022-03-24

6.  Breast cancer among Asian Indian and Pakistani Americans: A surveillance, epidemiology and end results-based study.

Authors:  Jaya M Satagopan; Antoinette Stroup; Anita Y Kinney; Tina Dharamdasani; Shridar Ganesan; Elisa V Bandera
Journal:  Int J Cancer       Date:  2020-10-25       Impact factor: 7.396

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.